Evidence map›Paper›PMID 33953961›Full record

ArticleCell & gene therapy insights2020

Improving therapeutic potential of non-viral minimized DNA vectors.

Lirio M Arévalo-Soliz, Cinnamon L Hardee, Jonathan M Fogg, Nathan R Corman, Cameron Noorbakhsh, Lynn Zechiedrich

Abstract read
In one paragraph

Article in Cell & gene therapy insights, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Review
  9. Review
  10. Review
  11. Review
  12. Article
  13. Article
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Lirio M Arévalo-SolizDepartment of Molecular Virology and Microbiology, Baylor College of Medicine, Houston, TX 77030, USA.
Cinnamon L HardeeDepartment of Molecular Virology and Microbiology, Baylor College of Medicine, Houston, TX 77030, USA.
Jonathan M FoggDepartment of Molecular Virology and Microbiology, Baylor College of Medicine, Houston, TX 77030, USA.
Nathan R CormanRural Medical Education Program, University of Illinois College of Medicine, Rockford, IL 61107, USA.
Cameron NoorbakhshWeiss School of Natural Sciences, Rice University, Houston, TX 77005, USA.
Lynn ZechiedrichDepartment of Molecular Virology and Microbiology, Baylor College of Medicine, Houston, TX 77030, USA.

Funding

Harnessing Supercoiling to Regulate DNA ActivityR35GM141793 · NIGMS · BAYLOR COLLEGE OF MEDICINE · PI ZECHIEDRICH, LYNN · 2021 to 2025
$2.1M
S2: Molecular Mechanisms Underlying Fluoroquinolone Susceptibility and ResistanceR01GM115501 · NIGMS · BAYLOR COLLEGE OF MEDICINE · PI ZECHIEDRICH, LYNN · 2015 to 2018
$1.7M
NIGMS NIH HHS R01 GM115501NIGMS NIH HHS R35 GM141793
6 · The paper itself

Abstract

The tragic deaths of three patients in a recent AAV-based X-linked myotubular myopathy clinical trial highlight once again the pressing need for safe and reliable gene delivery vectors. Non-viral minimized DNA vectors offer one possible way to meet this need. Recent pre-clinical results with minimized DNA vectors have yielded promising outcomes in cancer therapy, stem cell therapy, stem cell reprograming, and other uses. Broad clinical use of these vectors, however, remains to be realized. Further advances in vector design and production are ongoing. An intriguing and promising potential development results from manipulation of the specific shape of non-viral minimized DNA vectors. By improving cellular uptake and biodistribution specificity, this approach could impact gene therapy, DNA nanotechnology, and personalized medicine.

Identifiers

PMID33953961
PMCPMC8095377

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.